Who's who in the kean lab?
The Kean lab spreads from Boston to Seattle and everywhere in between! Our lab is broken out into two main sections, the clinical and lab teams! Of course, we wouldn't be Kean Lab without all of our collaborators as well. Get to know the whole Kean Lab below and be sure to check out all of the pages.
|
Dr. LEslie Kean, MD PhDDirector, Stem Cell Transplantation Program
Division of Hematology/Oncology, Boston Children’s Hospital Department of Pediatric Oncology, Dana-Farber Cancer Institute Robert A. Stranahan Professor of Pediatrics, Harvard Medical School |
Leslie S. Kean, MD PhD, is a clinician-scientist with extensive laboratory and clinical expertise in transplantation immunology. She is the Director of Pediatric Stem Cell Transplant at Boston Children’s Hospital and the Dana-Farber Cancer Institute, and a Full Professor at Harvard University. Dr. Kean spent the early part of her training at Emory University School of Medicine where she received her MD/PhD and completed her residency and fellowship. Before, coming to Boston Children's, Dr. Kean was an associate professor at Seattle Children's Hospital.
Dr. Kean’s research program is focused on the immunology of hematopoietic stem cell transplantation. The overarching goal of her research is to understand mechanisms underlying immune tolerance after transplantation, with a specific focus on mixed-chimerism induction for solid organ transplantation, graft-versus-host disease (GvHD), transplant rejection, and the reconstitution of protective immunity after transplantation. Dr. Kean’s work on mixed-chimerism, transplant rejection and GvHD has led to the creation of novel, MHC-defined non-human primate models of both engraftment and GvHD and to several first-in-disease clinical trials. She has used both the animal models and the mechanistic studies linked to her clinical trials to investigate the cellular and molecular mechanisms of immune reconstitution, GvHD and transplant rejection, and to test the impact that novel immunosuppressive therapies can make on these processes.
Dr. Kean’s research program is focused on the immunology of hematopoietic stem cell transplantation. The overarching goal of her research is to understand mechanisms underlying immune tolerance after transplantation, with a specific focus on mixed-chimerism induction for solid organ transplantation, graft-versus-host disease (GvHD), transplant rejection, and the reconstitution of protective immunity after transplantation. Dr. Kean’s work on mixed-chimerism, transplant rejection and GvHD has led to the creation of novel, MHC-defined non-human primate models of both engraftment and GvHD and to several first-in-disease clinical trials. She has used both the animal models and the mechanistic studies linked to her clinical trials to investigate the cellular and molecular mechanisms of immune reconstitution, GvHD and transplant rejection, and to test the impact that novel immunosuppressive therapies can make on these processes.
